| Alirocumab and cardiovascular outcomes after acute coronary syndrome GG Schwartz, PG Steg, M Szarek, DL Bhatt N Engl J Med 379 (22), 2097-2107, 2018 | 2623 | 2018 |
| Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis SR Ytterberg, DL Bhatt, TR Mikuls, GG Koch, R Fleischmann, JL Rivas, ... New England Journal of Medicine 386 (4), 316-326, 2022 | 800 | 2022 |
| Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase … R Fleischmann, E Mysler, S Hall, AJ Kivitz, RJ Moots, Z Luo, R DeMasi, ... Lancet 390 (10093), 457-68, 2017 | 496 | 2017 |
| Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease‐modifying antirheumatic drug treatment R Fleischmann, M Schiff, D van der Heijde, C Ramos‐Remus, A Spindler, ... Arthritis & Rheumatology 69 (3), 506-517, 2017 | 420 | 2017 |
| Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial BR Rubin, R Burton, S Navarra, J Antigua, J Londono, KG Pryhuber, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2004 | 267 | 2004 |
| Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY … KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, OOC Investigators Lancet Diabetes Endocrinol. 7 (8), 618-628, 2019 | 246 | 2019 |
| Diagnosing tuberculous pericarditis H Reuter, L Burgess, W Van Vuuren, A Doubell QJM: An International Journal of Medicine 99 (12), 827-839, 2006 | 229 | 2006 |
| Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double‐blind, placebo‐controlled trials MEB Clowse, DJ Wallace, RA Furie, MA Petri, MC Pike, P Leszczyński, ... Arthritis & rheumatology 69 (2), 362-375, 2017 | 222 | 2017 |
| Epidemiology of pericardial effusions at a large academic hospital in South Africa H Reuter, LJ Burgess, AF Doubell Epidemiology & Infection 133 (3), 393-399, 2005 | 215 | 2005 |
| The use of adenosine deaminase and interferon-γ as diagnostic tools for tuberculous pericarditis LJ Burgess, H Reuter, ME Carstens, JJF Taljaard, AF Doubell Chest 122 (3), 900-905, 2002 | 211 | 2002 |
| Psychopathology and coping in recently diagnosed HIV/AIDS patients-the role of gender BO Olley, F Gxamza, S Seedat, H Theron, J Taljaard, E Reid, H Reuter, ... South African Medical Journal 93 (12), 928-931, 2003 | 147 | 2003 |
| Critical evaluation of causality assessment of herb–drug interactions in patients C Awortwe, M Makiwane, H Reuter, C Muller, J Louw, B Rosenkranz British journal of clinical pharmacology 84 (4), 679-693, 2018 | 139 | 2018 |
| From suspect to patient: tuberculosis diagnosis and treatment initiation in health facilities in South Africa E Botha, S Den Boon, KA Lawrence, H Reuter, S Verver, CJ Lombard, ... The International Journal of Tuberculosis and Lung Disease 12 (8), 936-941, 2008 | 135 | 2008 |
| Beijing and Haarlem genotypes are overrepresented among children with drug-resistant tuberculosis in the Western Cape Province of South Africa BJ Marais, TC Victor, AC Hesseling, M Barnard, A Jordaan, W Brittle, ... Journal of Clinical Microbiology 44 (10), 3539-3543, 2006 | 131 | 2006 |
| Infective endocarditis in the Western Cape Province of South Africa: a three‐year prospective study CFN Koegelenberg, AF Doubell, H Orth, H Reuter Qjm 96 (3), 217-225, 2003 | 107 | 2003 |
| The management of tuberculous pericardial effusion: experience in 233 consecutive patients H Reuter, LJ Burgess, VJ Louw, AF Doubell Clinics Cardiv Publishing, 2007 | 106 | 2007 |
| Determinants of unprotected sex among HIV-positive patients in South Africa BO Olley, S Seedat, F Gxamza, H Reuter, DJ Stein AIDS care 17 (1), 1-9, 2005 | 101 | 2005 |
| Role of biochemical tests in the diagnosis of large pericardial effusions LJ Burgess, H Reuter, JJF Taljaard, AF Doubell Chest 121 (2), 495-499, 2002 | 83 | 2002 |
| Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis AA Abulfathi, EH Decloedt, EM Svensson, AH Diacon, P Donald, H Reuter Clinical pharmacokinetics 58, 1103-1129, 2019 | 81 | 2019 |
| Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate DM Gerlag, S Hollis, M Layton, J Vencovský, Z Szekanecz, M Braddock, ... Arthritis & Rheumatism 62 (11), 3154-3160, 2010 | 68 | 2010 |
Ben MaraisUniversity of SydneyVerified email at sydney.edu.au
